Full Version - English
Review the most important changes to the WHO hematopathology classification system as part of the 2016 revision. Emphasis will be placed on presenting the information so that it is relevant and understandable by non-hematopathologists and laboratory staff. This will be a two-part presentation, with the first lecture covering lymphoid neoplasms and the second presentation covering myeloid and precursor neoplasms. September 15, 2016 was part one of the series.
- Understand the need for the 2016 revision to the 2008 WHO hematopathology classification system.
- Review pertinent changes involving lymphoid neoplasms in a manner understandable by general pathologists and laboratory staff.
- Illustrate important situations where advanced testing (e.g. IHC, molecular, FISH) may be helpful in further distinguishing hematopoietic neoplasms, which had been difficult to classify or confirm with certainty in the past.
Leica Biosystems webinars, training presentations and related materials provide general information regarding particular subjects and are not intended to be, and should not be construed as medical, regulatory or legal advice. The views and opinions expressed are the personal views and opinions of the speaker(s)/author(s) and do not necessarily represent or reflect the views or opinions of Leica Biosystems, its employees or agents.
For the use of any product, the product information guides, inserts and operation manuals of the various products and devices should be consulted. Leica Biosystems and the editors disclaim any liability arising directly or indirectly from the use of devices, techniques or procedures described in these materials.
Copyright © 2018 by Leica Biosystems Richmond Inc. All rights reserved.LEICA and the Leica Logo are registered trademarks of Leica Microsystems